Medicines Patent Pool ads

Your incretin pipeline has global relevance. Demand for GLP-1–based therapies is accelerating across low- and middle income markets. Evidence suggests non-originator channels can expand patient reach significantly. MPP offers a structured, non-exclusive, quality-assured licensing pathway that helps innovators expand access, unlock additional revenue segments, and reduce operational complexity. Explore a responsible global access strategy for GLP-1 therapies and next-generation insulins. Request a confidential briefing.

As cardiometabolic innovation continues to evolve, how can innovators plan for broader global access while maintaining a structured, sustainable approach? Voluntary licensing can provide a pathway to extend reach across low- and middle-income countries, while reducing the complexity of managing multiple partnerships. Medicines Patent Pool works with originator companies through a structured, non-exclusive licensing model – from partner selection and quality requirements through to ongoing licence management and implementation. The result is a managed approach designed to support broader reach, quality-assured supply and long-term sustainability. Explore how the MPP model can support your global access strategy. Request a confidential briefing.

MPP partners with innovators to explore voluntary licensing models that can expand patient reach in low- and middle-income countries while maintaining a structured implementation approach. If you’re reviewing global access strategies for incretin therapies, we’d welcome a conversation. https://lnkd.in/d_hGw8WT

Evidence across 22 lower- and upper-middle-income countries shows non-originator channels can reach ~4× more patients than originator products alone. Voluntary licensing expands reach while remaining economically viable for originators. MPP provides a structured, quality-focused licensing model designed to protect commercial interests. https://lnkd.in/d_hGw8WT

Managing bilateral licences across multiple countries can be costly and resource-intensive. MPP’s Value Report estimates that licensing one product across 22 LMICs and UMICs can cost up to USD 10M annually in consultancies and partnership management – costs avoided through MPP’s managed model. https://lnkd.in/d_hGw8WT

MPP’s Value Report indicates voluntary licensing can unlock ~2–17% additional revenue potential in upper-middle-income countries through royalty mechanisms, while expanding patient reach. MPP provides a managed licensing model designed to support access at scale with strong quality safeguards. https://lnkd.in/d_hGw8WT